Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Neonatal crystallizable fragment receptor (FcRn)
- Target
- FcRn
- Molecular classification
- Receptor, Non-classical Fc gamma receptor
01
Overview
The neonatal crystallizable fragment receptor (FcRn), also known as the Brambell receptor, is a protein that plays a crucial role in the homeostasis of IgG and albumin. It mediates the transfer of maternal IgG to the fetus/neonate and protects IgG and albumin from lysosomal degradation, thus extending their half-lives. It is expressed in various cell types and tissues, including the placenta, kidney, intestine, and liver. FcRn is an important therapeutic target, particularly for autoimmune diseases, hematologic conditions, and certain kidney disorders.
- Other names
- Brambell receptorFCGRT
02
Mechanism of action
Inhibition of FcRn leads to accelerated degradation of circulating pathogenic IgGs.
03
Biological functions
Maternal IgG transportAlbumin & IgG recyclingAntigen processing/presentationRegulation of IgG homeostasisRegulation of albumin homeostasis
04
Disease associations
Autoimmune diseasesRenal diseaseHematologic conditions
05
Safety considerations
Selective loss/reduction of only the IgG pool may lower infection risk compared with pan-immunosuppression but could increase susceptibility to certain infections if not carefully monitored.
Beyond the preview
Go deeper on Neonatal crystallizable fragment receptor (FcRn).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Neonatal crystallizable fragment receptor (FcRn).